The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 31, Issue 3-4, 1998, Pages 317-323

  Drobyski, William R ^a,b   Hessner, Martin J ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

Chronic myeloid leukemia; CML; PCR; Predicting relapse; Unrelated marrow transplant

Indexed keywords

BCR ABL PROTEIN; INTERFERON;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; T LYMPHOCYTE; TREATMENT FAILURE;

EID: 0032425748     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809059224     Document Type: Article

References (27)

1. Roth MS, Antin JH, Bingham EL, Ginsburg D (1989). Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplantation for chronic myelogenous leukemia. Blood, 74, 882.
2. Roth MS, Antin JH, Ash R, Terry VH, Gotlieb M, Silver SM, Ginsburg D (1992). Prognostic significant of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood, 79, 276.
3. Delage R, Soiffer RJ, Dear K, Ritz J (1991). Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood, 78, 2759.
4. Hughes TP, Morgan GJ, Martiat P, Goldman JM (1991). Detection of residual leukemia after bone marrow transplantation for chronic myeloid leukemia: Role of polymerase chain in predicting relapse. Blood, 77, 874.
5. Miyamura K, Barrett AJ, Kodera Y, Saito H (1994). Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: A review of recent results. Bone Marrow Transplantation, 14, 201.
6. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM (1993). Competitive polymerase chain reaction to estimate the number of bcr-abl transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood, 82, 1929.
7. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H (1993). Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukemia. Lancet, 341, 275.
8. Thompson JD, Brodsky I, Yunis JJ (1992). Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation. Blood, 79, 1629.
9. Goldman JM, Gale RP, Horowitz MM, Biggs JC,et al (1988). Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion. Ann Int Med, 108, 806.
10. Mitsuyasu RT, Champlin RE, Gale RP Ho WG, et al (1986). Treatment of donor bone marrow with monoclonal anti-T cell antibody and complement for the prevention of graft-versus-host disease: A prospective, randomized, double-blind trial. Ann Intern Med, 105, 20.
11. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, et al (1991). T-cell depletion of HLA-identical transplants in leukemia. Blood, 78, 2120.
12. Horowitz MM, Gale RP, Sondel PM, Goldman JM, et al (1990). Graft-versus-leukemia reactions after bone marrow transplantation. Blood, 75, 555.
13. Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR (1995). Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T cell depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood, 86, 3987.
14. Drobyski WR, Ash RC, Casper JT, McAuliffe T, et al (1994). Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood, 83, 1980.
15. Waid TH, Lucas BA, Amlot P, Janossy G, Yacoub M, Cammisuli S, Jezek D, Rhoades J, Brown S, Thompson JS(1989). TIOB9. IA-31 anti-T cell monoclonal antibody: Preclinical studies and clinical treatment of solid organ allograft rejection. American Journal of Kidney Diseases, 14(5 Suppl 2), 61.
16. Hessner MJ, Roth MS, Drobyski WR, Baxter-Lowe LA (1994). Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia. Genetic Analysis, Techniques and Applications, 11, 90.
17. Radich JP, Gehly G, Gooley T, Bryant E, et al (1995). Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia. Results and implications in 346 patients. Blood, 85, 2632.
18. Higano CS, Raskind WH, Singer JW (1992). Use of Alpha interferon for treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood, 80, 1437.
19. Higano CS, Chielens D, Raskind W, Bryant E, et al (1997). Use of α-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood, 90, 2549.
20. Kolb HJ, Mittermuller J, Clemm CH, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns (1990). Donor leukocyte infusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood, 76, 2462.
21. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, et al (1995). Graft-versus-leukemia effect of donor lymphocyte infusions in marrow grafted patients. Blood, 86, 2041.
22. Drobyski, WR, Keever CA, Roth MS, Koethe S, et al (1993). Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood, 82, 2310.
23. Collins R. Shpilberg O, Drobyski W, Porter D, et al (1997). Donor Leukocyte Infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology, 15, 433.
24. Arcese W, Goldman JM, D'Arcangelo E, Schattenberg A, et al.(1993). Outcome of patients with relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood, 82, 3211.
25. MacKinnon S, Papadopoulos EB, Carabasi MH, Reich L, et al (1995). Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 86, 1261.
26. McGlave P, Kollman C, Shu XO, Anasetti C, Nademanee A, Champlin R, Antin J, Kernan N, King R (1996). The first 1000 unrelated donor transplants for CML: Lessons from the National Marrow Donor Program experience. Blood, 88, 483a.
27. Keman A, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A, Gajewski J, Hansen JA, Henslee-Downey J, McCullough J, McGlave P, Perkins HA, Phillips GL, Sanders J, Stroncek D, Thomas ED, Blume KG (1993). Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. New England Journal of Medicine 328, 593.